In contrast, those with severe psoriasis (BSA > 10%) and PsA may require biologic therapy, including TNFi, IL-17i, IL-23i, or cytotoxic T-lymphocyte-associated-antigen-4-Ig (CTLA4-Ig) agents [53]. Here, CTLA4 is linked to psoriasis.